Pharmaceutical composition, methods for treating and uses thereof
Uli Christian Broedl, Mainz (DE); Odd-Erik Johansen, Hoevik (NO); Gabriel Woojai Kim, Mainz am Rhein (DE); Eric Williams Mayoux, Neauphle-le-Vieux (FR); Afshin Salsali, Princeton, NJ (US); Nima Soleymanlou, Maple (CA); Maximilian von Eynatten, Wiesbaden (DE); Hans-Juergen Woerle, Grandvaux (CH); David Z.I. Cherney, Toronto (CA); Bruce A. Perkins, Toronto (CA); Andreas Daiber, Scheessel (DE); and Thomas Muenzel, Mainz (DE)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim an Rhein (DE)
Filed by Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed on Jul. 21, 2021, as Appl. No. 17/381,498.
Application 17/381,498 is a continuation of application No. 16/804,153, filed on Feb. 28, 2020, abandoned.
Application 16/804,153 is a continuation of application No. 15/945,236, filed on Apr. 4, 2018, abandoned.
Application 15/945,236 is a continuation of application No. 15/933,706, filed on Mar. 23, 2018, abandoned.
Application 15/933,706 is a continuation of application No. 14/855,576, filed on Sep. 16, 2015, abandoned.
Application 14/855,576 is a continuation in part of application No. 14/244,196, filed on Apr. 3, 2014, abandoned.
Claims priority of provisional application 61/942,301, filed on Feb. 20, 2014.
Claims priority of provisional application 61/835,811, filed on Jun. 17, 2013.
Claims priority of provisional application 61/835,809, filed on Jun. 17, 2013.
Claims priority of provisional application 61/823,041, filed on May 14, 2013.
Claims priority of provisional application 61/808,807, filed on Apr. 5, 2013.
Prior Publication US 2022/0110961 A1, Apr. 14, 2022
1. A method for reducing the risk of cardiovascular death and/or hospitalization for heart failure in a patient with heart failure, said method comprising administering a therapeutically effective amount of empagliflozin to the patient.